Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- SWCH -10.8%
Other news:
- LFIN -24.5% (filed 10-K disclosing details of March 5 Division of Enforcement of the SEC investigation)
- RIGL -8.8% (announces topline data from proof-of-concept phase 2 study of Fostamatinib in IgA Nephropathy; trial did not achieve statistical significance for its primary endpoint)
- VIAB -6.4% (Reuters reporting that CBS proposal will be below Viacom's current market valuation)
- ENPH -2.9% (light volume; files for 9,523,809 share common stock offering by selling stockholder)
- PTN -1.8% (presents poster on preclinical studies of an oral formulation of PL-8177)
Analyst comments:
- GME -1.6% (downgraded to Hold from Buy at Loop Capital)
- STZ -0.7% (downgraded to Hold at Stifel)
- WFT -0.5% (downgraded to Neutral from Overweight at Piper Jaffray)